Literature DB >> 31785257

Adiponectin and leptin in the diagnosis and therapy of NAFLD.

Chrysoula Boutari1, Christos S Mantzoros2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31785257     DOI： 10.1016/j.metabol.2019.154028

Source DB:  PubMed          Journal:  Metabolism        ISSN： 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  17 in total

1.  Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study.

Authors:  Itziar Abete; M Angeles Zulet; Nuria Perez-Diaz-Del-Campo; Bertha Araceli Marin-Alejandre; Irene Cantero; J Ignacio Monreal; Mariana Elorz; José Ignacio Herrero; Alberto Benito-Boillos; Jose I Riezu-Boj; Fermín I Milagro; Josep A Tur; J Alfredo Martinez
Journal:  Eur J Nutr       Date:  2021-01-20       Impact factor: 5.614

Review 2.  Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue.

Authors:  Courtney L Hanlon; Liyun Yuan
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-01-28

Review 3.  Severe insulin resistance syndromes.

Authors:  Angeliki M Angelidi; Andreas Filippaios; Christos S Mantzoros
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

4.  Effects of wogonoside on the inflammatory response and oxidative stress in mice with nonalcoholic fatty liver disease.

Authors:  Guangyu Jiang; Dayin Chen; Wenpeng Li; Chengcheng Liu; Jiguang Liu; Yingxue Guo
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

Review 5.  Role of Leptin in the Digestive System.

Authors:  Min-Hyun Kim; Hyeyoung Kim
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

Review 6.  Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk.

Authors:  Siarhei A Dabravolski; Evgeny E Bezsonov; Mirza S Baig; Tatyana V Popkova; Ludmila V Nedosugova; Antonina V Starodubova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 7.  MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.

Authors:  Nancy de Los Ángeles Segura-Azuara; Carlos Daniel Varela-Chinchilla; Plinio A Trinidad-Calderón
Journal:  Front Med (Lausanne)       Date:  2022-01-13

Review 8.  Role of Leptin in Non-Alcoholic Fatty Liver Disease.

Authors:  Carlos Jiménez-Cortegana; Alba García-Galey; Malika Tami; Pilar Del Pino; Isabel Carmona; Soledad López; Gonzalo Alba; Víctor Sánchez-Margalet
Journal:  Biomedicines       Date:  2021-06-30

Review 9.  The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Claudia Florida Costea; Manuela Ciocoiu; Cristina Mihaela Lacatusu; Minela Aida Maranduca; Anca Ouatu; Mariana Floria
Journal:  J Diabetes Res       Date:  2020-07-31       Impact factor: 4.011

10.  Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis.

Authors:  Ping-Hsiao Shih; Sheng-Jie Shiue; Chun-Nan Chen; Sheng-Wei Cheng; Hsin-Yi Lin; Li-Wei Wu; Ming-Shun Wu
Journal:  Mar Drugs       Date:  2021-03-12       Impact factor: 5.118
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.